Skip to content
Learn More

Resources

iBio Expands Immuno-Oncology Pipeline in AI Partnership with RubrYc Therapeutics

August 25, 2021

SAN DIEGO and BRYAN, Texas, Aug. 25, 2021 (GLOBE NEWSWIRE) — iBio, Inc., a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today announced that it has signed a definitive worldwide exclusive license agreement with RubrYc Therapeutics, Inc., for RTX-003, an immunotherapy candidate targeting regulatory T cells (Tregs).

Read More

iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate

July 15, 2021

BRYAN, Texas, July 15, 2021 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that preclinical studies of IBIO-202, its subunit vaccine candidate that targets the nucleocapsid protein (“N protein”) of SARS-CoV-2, demonstrated a robust, antigen-specific, memory T-cell response. Data on commercially available COVID-19 …

Read More

iBio Establishes Oncology Drug Discovery Pipeline with Three New Antibody Programs

July 8, 2021

BRYAN, Texas, July 08, 2021 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, has taken another major step towards leveraging the speed and throughput of its proprietary, plant-based FastPharming Protein Expression System® by announcing today it is adding three anti-cancer targets to its pipeline of therapeutic candidates. …

Read More

iBio Reports Successful COVID-19 Vaccine Toxicology Study Results and Announces Next-Gen COVID-19 Vaccine Program

May 6, 2021

BRYAN, Texas, May 06, 2021 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today provided an update on its IBIO-201 program and reported on its progress in developing a second-generation subunit vaccine candidate, IBIO-202, being designed for the prevention of SARS-CoV-2 infection. IBIO-201, the Company’s vaccine candidate …

Read More

iBio Appoints Robert M. Lutz as Chief Financial & Business Officer

February 16, 2021

BRYAN, Texas, Feb. 16, 2021 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Robert M. Lutz as its Chief Financial & Business Officer (“CFBO”), effective March 4, 2021. “I am pleased to welcome Rob to iBio where we expect he …

Read More
Top